التفاصيل البيبلوغرافية
| العنوان: |
The Clinical Pharmacology of Intranasal l-Methamphetamine |
| المؤلفون: |
Mendelson, John E, McGlothlin, Dana, Harris, Debra S, Foster, Elyse, Everhart, Tom, Jacob, Peyton, Jones, Reese T |
| بيانات النشر: |
BioMed Central Ltd. |
| سنة النشر: |
2008 |
| المجموعة: |
BioMed Central |
| الوصف: |
Background We studied the pharmacology of l-methamphetamine, the less abused isomer, when used as a nasal decongestant. Methods 12 subjects self-administered l-methamphetamine from a nonprescription inhaler at the recommended dose (16 inhalations over 6 hours) then at 2 and 4 (32 and 64 inhalations) times this dose. In a separate session intravenous phenylephrine (200 μg) and l-methamphetamine (5 mg) were given to define alpha agonist pharmacology and bioavailability. Physiological, cardiovascular, pharmacokinetic, and subjective effects were measured. Results Plasma l-methamphetamine levels were often below the level of quantification so bioavailability was estimated by comparing urinary excretion of the intravenous and inhaled doses, yielding delivered dose estimates of 74.0 ± 56.1, 124.7 ± 106.6, and 268.1 ± 220.5 μg for ascending exposures (mean 4.2 ± 3.3 μg/inhalation). Physiological changes were minimal and not dose-dependent. Small decreases in stroke volume and cardiac output suggesting mild cardiodepression were seen. Conclusion Inhaled l-methamphetamine delivered from a non-prescription product produced minimal effects but may be a cardiodepressant. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| العلاقة: |
http://www.biomedcentral.com/1472-6904/8/4Test |
| الإتاحة: |
http://www.biomedcentral.com/1472-6904/8/4Test |
| حقوق: |
Copyright 2008 Mendelson et al; licensee BioMed Central Ltd. |
| رقم الانضمام: |
edsbas.9EEF99D6 |
| قاعدة البيانات: |
BASE |
